home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630594.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
3KB
|
47 lines
Document 0594
DOCN M9630594
TI Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2
recombinant Salmonella vaccines, induce long-lasting protection in
rhesus macaques.
DT 9603
AU Franchini G; Robert-Guroff M; Tartaglia J; Aggarwal A; Abimiku A; Benson
J; Markham P; Limbach K; Hurteau G; Fullen J; et al; Laboratory of Tumor
Cell Biology, National Cancer Institute,; National Institutes of Health,
Bethesda, Maryland 20892, USA.
SO AIDS Res Hum Retroviruses. 1995 Aug;11(8):909-20. Unique Identifier :
AIDSLINE GENBANK/J04498
AB Immunization schemes employing priming with vector-based vaccine
candidates followed by subunit booster administrations have been
explored and shown to have merit in the human immunodeficiency virus
type 1 (HIV-1) and simian immunodeficiency virus systems. In this study,
we have assessed the priming capacity of highly attenuated poxvirus
vector (NYVAC and ALVAC)-based HIV-2 recombinants, as well as Salmonella
typhimurium HIV-2 recombinants in rhesus macaques. ALVAC- and
NYVAC-based vaccine candidates expressing the HIV-2 gag, pol, and env
genes or NYVAC-based recombinants expressing either gp160 or gp120 were
used to immunize rhesus macaques in combination protocols with
alum-adjuvanted HIV-2 rgp160. Following intravenous challenge exposure
with 100 infectious doses of the HIV-2SBL6669 parental virus genotype
mixture, seven of eight animals were protected from infection. The seven
protected animals were rechallenged 6 months postprimary challenge,
without additional booster inoculations, with the same dose of the
HIV-2SBL6669 parental virus. Five of the seven animals remained
protected against HIV-2 infection at 6 months following the second
challenge. In contrast, oral immunization with recombinant Salmonella
expressing the HIV-2 gag and the gp120 portion of the envelope either
alone or in combination with alum-adjuvanted rgp160 failed to confer
protection. These results suggest that the NYVAC- and ALVAC-based
recombinants may confer long-lasting protection and that these two
highly attenuated poxvirus vaccine vectors may represent promising
candidates for developing an acquired immunodeficiency syndrome vaccine.
DE Amino Acid Sequence Animal Base Sequence Genetic Vectors Human HIV
Infections/IMMUNOLOGY/*PREVENTION & CONTROL HIV-2/GENETICS/*IMMUNOLOGY
Macaca mulatta Molecular Sequence Data Poxviridae/GENETICS
Salmonella/GENETICS Support, Non-U.S. Gov't Vaccines,
Synthetic/GENETICS/IMMUNOLOGY/*THERAPEUTIC USE Viral
Proteins/GENETICS/*IMMUNOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).